Quantcast

Industry news that matters to you.  Learn more

New Technology May Enable Earlier Cancer Diagnosis

Finding ways to diagnose cancer earlier could greatly improve the chances of survival for many patients. One way to do this is to look for specific proteins secreted by cancer cells, which circulate in the bloodstream. However, the quantity of these biomarkers is so low that detecting them has proven difficult.

Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option for Reducing Recurrent Heart Attack Risk, Early CSL Studies Show

Infusions of a novel formulation of apolipoprotein A-I (apoA-I) – the main component of high-density lipoprotein (HDL) – rapidly increased the presence of key biomarkers associated with reverse cholesterol transport, a process by which cholesterol is removed from arteries and transported to the liver for clearance, according to data from a Phase 1 study sponsored by CSL Limited. Rapid removal of cholesterol following a heart attack may play a role in stabilizing vulnerable plaque lesions and lowering the high risk of subsequent attacks.

Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine

Gentris Corporation, a global leader in the application of genomic biomarkers to clinical studies, announced today that it has signed a Memorandum of Understanding with the Shanghai Institutes of Preventative Medicine to advance global personalized medicine. The goal of this USA-China collaboration is to create translational research and epidemiological projects, as well as training and education programs, focused on pharmacogenomics and clinical sample banking, which will drive innovation in drug development and improvements in patient care.

GW Researchers Discover Biomarker for Advanced Bile Duct Fibrosis and Bile Duct Cancer

GW Researchers, Jeffrey M. Bethony, Ph.D., associate professor of Microbiology, Immunology, and Tropical Medicine, and Paul Brindley, Ph.D., professor of Microbiology, Immunology, and Tropical Medicine at GW School of Medicine and Health Sciences, along with colleagues from Khon Kaen University in Thailand have determined that plasma Interleukin-6 (IL-6) levels are an sensitive and specific biomarker for the detection of the advanced bile duct fibrosis and bile duct cancer that comes from chronic infection with the Asian Liver Fluke (Opisthorchis viverrini). The research, titled, “Elevated Plasma IL-6 Associates with Increased Risk of Advanced Fibrosis and Cholangiocarcinoma in Individuals Infected by Opisthorchis viverrini,” was recently published in the journal, PLoS Neglected Tropical Diseases.

Courtagen Submits Pre-IDE Information Package for the Avantra Q400 Workstation and QPDx BioChip

Courtagen Life Sciences, Inc., a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced that the company has submitted its first pre- IDE (Investigational Device Exemption) information package to the U.S. Food and Drug Administration for the Company’s Avantra® Q400 BioMarker Workstation and QPDX® BioChip for the measurement of C-reactive protein (CRP). Courtagen is also pursuing a CE Mark Approval for the European Union.